Detection and treatment of excessive hair shedding
The present invention relates to a method of treating or preventing hair loss or excessive hair shedding in a subject by administering to a subject an oral dose of minoxidil. In particular, the present invention relates to a method of treating telogen effluvium in a subject by administering to a subject an oral dose of minoxidil.
1. A method of treating alopecia areata in a subject by administering to a subject an oral dose of minoxidil within the range from about 0.1 mg to 2.5 mg daily.
2. The method according to claim 1 , which further comprises administering a: aldosterone antagonist, 5α-reductase inhibitor, non-steroidal antiandrogen drug and/or a steroidal antiandrogen.
3. The method according to claim 1 , which further comprises administering spironolactone within the range of from about 10 mg to 500 mg.
4. The method according to claim 3 , wherein spironolactone is at a concentration of about 25 mg.
5. The method according to claim 1 , which further comprises administering sodium chloride with the range of from about 10 mg to 200 mg.
6. The method according to claim 5 , wherein sodium chloride is at a concentration of about 20 mg.
7. The method according to claim 1 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.
8. The method according to claim 1 , wherein the oral minoxidil dose is about 0.25 mg daily.
9. The method according to claim 8 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.
10. The method according to claim 1 , wherein the oral minoxidil dose is about 2.5 mg, or is about 1 mg, or is about 0.5 mg, or is about 0.25 mg daily.
11. The method according to claim 10 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.
12. The method according to claim 1 , wherein the oral minoxidil dose is about 2.5 mg daily.
13. The method according to claim 12 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.
14. The method according to claim 1 , wherein the oral minoxidil dose is about 2 mg daily.
15. The method according to claim 14 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.
16. The method according to claim 1 , wherein the oral minoxidil dose is about 1.5 mg daily.
17. The method according to claim 16 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.
18. The method according to claim 1 , wherein the oral minoxidil dose is about 1 mg daily.
19. The method according to claim 18 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.
20. The method according to claim 1 , wherein the oral minoxidil dose is about 0.75 mg daily.
21. The method according to claim 20 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.
22. The method according to claim 1 , wherein the oral minoxidil dose is about 0.5 mg daily.
23. The method according to claim 22 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.
24. The method according to claim 1 , wherein the oral minoxidil dose is about 0.49 mg, or is about 0.48 mg daily.
25. The method according to claim 24 , which additionally comprises administering one or more of:
(i) finasteride within the range of from about 0.1 mg to 1 mg;
(ii) dutasteride within the range of from about 0.01 mg to 1 mg;
(iii) flutamide within the range of from about 10 mg to 500 mg;
(iv) cyproterone acetate within the range of from about 1 mg to 100 mg;
(v) bicalutamide within the range of from about 1 mg to 100 mg;
(vi) enzalutamide within the range of from about 1 mg to 100 mg;
(vii) nilutamide within the range of from about 1 mg to 100 mg;
(viii) drosperidone within the range of from about 0.1 mg to 10 mg;
(ix) apalutamide within the range of from about 1 mg to 100 mg; and
(x) buseralin within the range of from about 0.1 mg to 10 mg.